中南大学 xu deng

Language : English

xu deng

Home

Journal Publications

Research Projects

Books

Patents

Teaching

Honors and Awards

Recommended MA Supervisor

MOBILE Version

Journal Publications

Current position: Home > Journal Publications

[1]Development of Strigolactones as Novel Autophagy/Mitophagy Inhibitors against Colorectal Cancer Cells by Blocking the Autophagosome–Lysosome Fusion[J]. America.Journal of Medicinal Chemistry, 2022, 65 (14) : 9706–9717.
[2]Acid-promoted intra-and intermolecular [2+ 2] cycloaddition of indoles with aryl alkynes to access cyclobutene-fused indolines[J]. 英国.Chemical Communications, 2022, 58: 9270-9273.
[3]Efficient Synthesis of Icetexane Diterpenes and Apoptosis Inducing Effect by Upregulating BiP-ATF4-CHOP Axis in Colorectal Cells[J]. USA.Journal of Natural Products, 2021
[4]Modular and scalable synthesis of nematode pheromone ascarosides: implications in eliciting plant defenses[J]. 伦敦.Organic & Biomolecular Chemistry, 2020
[5]Xu Deng, Yingjun Zhou, Yajing Wang, Jinjin Ma, Guangyao Zeng, Lingyang Yan, Jinbao Fan, Wei Cao.Divergent Reactivity in CuII-Catalyzed Oxidative Coupling between Indole/Tryptamine Derivatives and β-Arylacrylic Acids[J].Organic Letters, 2019, 21 (23) : 9506-9511.
[6]Jing, Zhongxian Tian, Jiawei Xu, Qipeng Xie, Yisi Luo, Jiheng Xu, Xu Deng, Maowen Huang, Xiaohui Hua.The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein[J].Cell Death & Differentiation, 2019, 28 (7)
[7]Lung-Wa; Zhang, Hui; Chung, Xiao-Yong; Lv, Yu-Qin; Zhang, Jia-Lin; Guan, Li-Yang; Lan, Xu; Shi, Deng.Enantioselective Rhodium-Catalyzed Cycloisomerization of 1,6-Allenynes to Access 5/6-Fused Bicyclo[4,3,0] Nanodiene[J].Nature Communications, 2019, 10: 949.
[8]Xu-Mu Zhang*, Li Dang*, Hui Lv, Yu-Qing Guan, Zheng-Yu Han, Shao-Fei Ni, Xu Deng.Enantioselective rhodium-catalyzed cycloisomerization of (E)-1,6-enynes[J].Angewandte Chemie International Edition,, 2016, 55: 6295-6299.
[9]Cheng-Feng Xia*, Da-Shan Li, Ming Ding, Xiao-Gang Tong, Kang-Jiang Liang, Xu Deng.Copper-catalyzed radical cyclization to access 3-hydroxypyrroloindoline: biomimetic synthesis of protubonine A[J].Organic Letters, 2014, 16: 3276-3279.
[10]Xu Deng, Yingjun Zhou, Yajing Wang, Chenxi Wang, Jinjin Ma, Guangyao Zeng, Jinbao Fan, Xiaofeng Chen.Access to 3a-Benzoylmethyl Pyrrolidino[2,3-b]indolines via CuII-Catalyzed Radical Annulation/C3-Functionalization Sequence[J].The Journal of Organic Chemistry, 2018, 83 (15) : 8322–8330.
[11]Xu-Mu Zhang, Hui Lv, Ya-Jing Wang, Ning-Ning Huo, Yu-Qing Guan, Xu Deng.An Efficient and Modular Route to C3*-TunePhos-Type Ligands[J].synthesis, 2017: 10.1055/s-0036-15884.
[12]Xu Deng, YingjunZhou, YuanjianLi, Yajing Wang, Guangyao Zeng, Wei Cao, Jinbao Fan, Lan Chen, Jinjin Ma.Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP[J]. Elsevier.European Journal of Medicinal Chemistry, 2019, 168 (15) : 146-153.
[13]Qin-Shi Zhao*, Ying Leng*, Li -Yan Peng, Yu Zhao, Juan He, Jing Yang, Yu Shen, Xu Deng.Discovery and Structure-Activity Relationships of ent-Kaurene Diterpenoids as Potent and Selective 11β-HSD1 Inhibitors: Potential Impact in Diabetes[J].European Journal of Medicinal Chemistry, 2013, 65: 403-414.
[14]Xu Deng & Yingjun Zhou, Yajing Wang, Wei Cao, Zhaoquan Wu, Guangyao Zeng.Identification of anti-nociceptive constituents from the pollen of Typha angustifolia L. using effect-directed fractionation[J].Natural Product Research, 2018
[15]Qin-shi Zhao*, Yan Li*, Li-Yan Peng, He, Juan, Yu Zhao, Ling-Mei Kong, Xu Deng.Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products[J].Natural products and Bioprospecting, 2012, 2: 210-216.
[16]Qin-Shi Zhao*, Zhu-Jun Yao*, Yan Li, Li-Yan Peng, Yu Zhao, Jia Su, Xu Deng.Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles[J].European Journal of Medicinal Chemistry, 2011, 46: 4238-4244.
[17]Y, Mei Dong, Yin-Yin Xie, Yi Jin, Yi-Jie Liu, Run Xiao, Ying Lu, Li-Dong Shao, Xu Deng#, Bai-Xin Ye#.Vibsanin B preferentially targets HSP90？, inhibit interstitial leukocyte migration and ameliorates experimental autoimmue encephalomyelitis[J].Journal of Immunology, 2015, 194: 4489.
[18]Fe, Dong-Yun Zhang, Yong-Hui Yu, Jing-Xia Li, Xu Deng#, Liang Chen#, Guang-Xun Gao#, Jing-Jie Zhang#.Cheliesisin A inhibits EGF-induced cell transformation with stablization of p53 protein via a hydrogen peroxide/Chk1 dependent axis[J].Cancer prevention Research, 2013, 6: 949-958.
[19]Yan Li*, Qin-Shi Zhao*, Han-Dong Sun, Zhi-Li Zuo, Xu Deng#, Ling-Mei Kong#.Identification and validation of P50 as the cellular target of Eriocalyxin B[J].Oncotarget, 2014, 5: 11354.
[20]Cheng-Feng Xia*, Da-Shan Li, Ming Ding, Xiao-Gang Tong, Xu Deng, Kang-Jiang Liang.Copper-mediated radical dimerization to access 3a,3a’-bispyrrolidinoindoline: diastereoselective synthesis of (+)-WIN 64821 and (-)-ditryptophenaline[J].Organic Letters, 2015, 17: 206-209.

total22 1/2

firstpreviousnext last Page